

Is there a link between COVID-19 and obstructive sleep apnea?

Cristina Salles¹
Juliana Rodrigues Lopes¹
Margarida Neves²
Renata Silva Brito^{1*}
Andrea Bacelar³

¹Escola Bahiana de Medicina e Saúde Pública, Pesquisa - Salvador - Bahia - Brazil

²Universidade Federal da Bahia - Salvador - Bahia - Brazil.

³Brazilian Sleep Association, President - Rio de Janeiro - Rio de Janeiro - Brazil.

ABSTRACT

Although obstructive sleep apnea syndrome (OSAS) is not considered a risk factor for COVID-19, studies have observed that these two conditions have comorbidities in common such as diabetes, cardiovascular diseases, asthma, obesity, hypertension, and chronic obstructive pulmonary disease. Thus, one may question the possible contribution of OSAS to the worsening of hypoxemia in patients with COVID-19 since OSAS and obesity (hypoventilation) are associated with hypoxemia, which can be a worsening factor in the hypoxemia of COVID-19 pneumonia. Moreover, one may question whether sleep deprivation would negatively interfere with the pulmonary condition caused by COVID-19. Another question would be whether sleep deprivation resulting from OSAS would be a favorable condition for the pulmonary inflammatory process in patients with COVID-19. Studies with a more significant number of participants are needed to assess the possible impact of OSAS on the outcomes of patients with SARS-CoV-2 infection, providing a more solid basis for making therapeutic decisions. An important advance in understanding the influence of OSAS on COVID-19 is represented by careful identification of comorbidities and potential pathophysiological mechanisms that may contribute to the favorable outcome of these patients.

Keywords: Coronavirus Infections; Obstructive Sleep Apnea; Sleep.

*Corresponding author:

Renata Silva Brito
E-mail: renatabrito15.2@bahiana.edu.br

Received: July 22, 2020;
Accepted: December 2, 2020.

DOI: 10.5935/1984-0063.20200078

INTRODUÇÃO

A novel human coronavirus, called coronavirus of severe acute respiratory syndrome 2 (SARS-CoV-2), emerged in Wuhan, China, in late 2019 and is now causing a pandemic¹. SARS-CoV-2 is considered being a respiratory virus capable of affecting both the upper and lower respiratory tracts. This syndrome has become a significant challenge to the healthcare community, governments, among other institutions².

Once the pandemic started, there was a need for social isolation, which led to the suspension or marked reduction of regular sports activities, an increase in calorie intake, thereby promoting weight gain; besides, the literature reports that the most significant predictor of weight gain in this period has been self-reported anxiety/depression, which consequently contributes to the worsening of obstructive sleep apnea syndrome (OSAS)³. Studies have shown that about 70% of OSAS patients are obese and that the opposite is also true, i.e., 40% of obese patients have OSAS⁴⁻⁶. There is an association between abdominal circumference and apnea-hypopnea index so that a 13-15cm increase in abdominal circumference raises the risk for OSAS by about 4 times^{7,8}. Hypoxemia and sleep fragmentation may be associated with increased inflammation in OSAS patients and may be identified by increased interleukin-6, C-reactive protein, tumor necrosis factor-alpha^{9,10}. Besides this factor, the coexistence of chronic non-communicable diseases, such as obesity, in patients with COVID-19 may worsen and intensify the inflammatory process, and increase the risk of adverse outcomes and mortality¹¹. The higher body mass index and excess adiposity carry risk factors for complications from COVID-19 infection. This condition may occur because of the higher prevalence of lung problems in obese populations compared to healthy weight counterparts¹².

A marked increase of interleukin 1, IL-2, IL-4, IL-6, IL-8, and IL-10, the so-called “cytokine storm”¹³, characterized by the extensive and uncontrolled release of pro-inflammatory cytokines, can be observed in this disease. Clinically, the cytokine storm usually presents as systemic inflammation and multiple organ failure¹⁴. In addition to these changes, hypoalbuminemia, lymphopenia, neutropenia, and oxidative stress can be observed¹⁵.

Although OSAS is not considered a risk factor for COVID-19, studies have shown the high frequency of this syndrome in intensive care unit patients due to the worsening of SARS-CoV-2 infection. McSharry and Malhotra (2020)¹⁶ draw attention to OSAS and COVID-19 because they have comorbidities in common such as diabetes, cardiovascular diseases, asthma, obesity, hypertension, and chronic obstructive pulmonary disease (Figure 1). These authors question about the possible contribution of OSAS to the worsening of hypoxemia in patients with COVID-19 since OSAS and obesity (hypoventilation) are associated with hypoxemia, which can be a worsening factor in the hypoxemia of COVID-19 pneumonia. On the other hand, they ask whether the benefits reported by early intubation in patients with COVID-19 could be related to OSAS improvement. No robust studies have been published yet to answer such questions. However, Bhatraju et al. (2020)¹⁷, when evaluating 24 patients with COVID-19 with a severe acute respiratory syndrome, in an intensive care unit (ICU) in Washington,

found that 21% (5) presented OSAS, a value higher than that found for established comorbidities as a risk factor, e.g., asthma (14%) and chronic obstructive pulmonary disease (4%). Arentz et al. (2020)¹⁸ found a similar result in their study when they evaluated 21 ICU patients with COVID-19 and observed that among the comorbidities, 28.6% were diagnosed with OSAS, a higher frequency than that found with asthma (9.1%) and with the use of immunosuppressants (14.3%).




Figure 1. Common comorbidities between COVID-19 and OSAS

During healthy sleep occurs the regulatory function of the immune response, with activation of T and B lymphocytes, release of pro- and anti-inflammatory cytokines¹⁹. However, patients with obstructive sleep apnea will present partial or complete obstruction of the upper airways, where airflow is decreased in hypopnea or completely interrupted in apnea, resulting in intermittent episodes of hypoxemia, hypercapnia, micro-awakenings and sleep fragmentation²⁰. Therefore, patients with OSAS associated with sleep deprivation may present an increased production of inflammatory cytokines with marked neutrophilia. Nunes et al. (2018)¹⁹ conducted an experimental study comparing the pulmonary inflammatory response in mice exposed to the allergen (ovalbumin) that had a healthy sleep with those in sleep deprivation. They concluded that mice in sleep deprivation presented a greater inflammatory process in the airways than those with healthy sleep. Given this scenario, Salles (2020)²¹ questioned whether sleep deprivation would negatively interfere with the pulmonary condition resulting from COVID-19. Afterward, this question became more restricted, i.e., Salles and Barbosa (2020)²² questioned whether sleep deprivation resulting from OSAS would be a favorable condition for the pulmonary inflammatory process in patients with COVID-19 (Figure 2). Tufik et al. (2020)²³ suggest the potential contribution of intermittent hypoxia observed in OSAS patients, which may interfere with the pulmonary ventilation, further compromising pulmonary parenchyma involvement, along with pulmonary vascular endothelial dysfunction resulting from the infectious response to SARS-CoV-2.




Figure 2. Association between comorbidities and aggravation COVID-19

Nunes et al. (2018)¹⁹ observed that the anti-inflammatory response of the corticoid in mice in sleep deprivation and with an inflammatory process in the airways was more resistant than in those who had a healthy sleep, i.e., they were not able to modulate interleukin-17 and tumor necrosis factor- α production. On the other hand, the World Health Organization recommends the use of corticosteroids for the management of COVID-19. It has been proposed that corticosteroids would be beneficial in suppressing lung inflammation in severe acute respiratory syndrome because of their immunomodulatory properties²⁴. Thus, we ask: could patients with OSAS and COVID-19 present greater resistance to corticoid treatment?

In line with the cited above, Grote et al. (2020)²⁵ observed that sleep medicine specialists have been following in the opposite direction of COVID-19, i.e., sleep medicine services were reduced by almost 80% during the first 1-2 months of the pandemic in Europe. Second, polysomnography and PAP titrations have been wholly discontinued or practiced only to a limited extent in highly selected groups of patients. Third, the onset of sleep-disordered breathing (SDB) treatment with PAP therapy has also been reduced in most countries. Fourth, patient follow-up is now managed mainly by phone contacts. Fifth, the potential of mitigation strategies available through telemedicine has not been explored. Thus, the authors conclude that the sleep medicine community needs to collaborate in the development of strategies to assist patients with sleep-disordered breathing during major events such as the COVID-19 pandemic. Activities need to focus on the recognition of severe cases of SDR.

Studies with a more significant number of participants are needed to assess the possible impact of OSAS on the outcomes of patients with SARS-CoV-2 infection, providing a more solid basis for making therapeutic decisions. An important advance in understanding the influence of OSAS on COVID-19 is represented by careful identification of comorbidities and potential pathophysiological

mechanisms that may contribute to the favorable outcome of these patients.

Thus, the present article demonstrates the need for further research considering the comparison of the severity of the clinical condition of individuals who were not diagnosed with OSAS but who were diagnosed with Covid-19 and those with OSAS and who were diagnosed with COVID-19. For better diagnostic elucidation, exclusion criteria could be presented in order to rule out confounding factors, i.e., comorbidities that could lead to a worse prognosis regarding COVID-19 infection (such as diabetes, systemic arterial hypertension, obesity, among other risk factors already established in the literature).

FUNDING

No source of funding.

REFERENCES

- Centers for Disease Control and Prevention (CDC). Information for healthcare professionals about coronavirus (COVID-19) [Internet]. Atlanta: CDC; 2019. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html>
- Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. *Int J Antimicrob Agents* [Internet]. 2020 Jun; 56(2):106054. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0924857920302247>
- Pellegrini M, Ponzio V, Rosato R, Scumaci E, Goitre I, Benso A, et al. Changes in weight and nutritional habits in adults with obesity during the “lockdown” period caused by the COVID-19 virus emergency. *Nutrients*. 2020 Jul;12(7):2016.
- Ministério da Saúde (BR). Secretaria Nacional de Ações Básicas de Saúde. Estatísticas de mortalidade. Brasília (DF): Ministério da Saúde; 2000.
- Asher MI. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). *Eur Respir J*. 1998 Aug;12(2):315-35.
- Tantisira KG, Weiss ST. Complex interactions in complex traits: obesity and asthma. *Thorax*. 2001 Sep;56(Suppl 2):ii64-73.
- Mello ED, Luft VC, Meyer F. Childhood obesity - towards effectiveness. *J Pediatr (Rio J)*. 2004;80(3):173-82.
- Figueroa-Muñoz JJ, Chinn S, Rona RJ. Association between obesity and asthma in 4-11 year old children in the UK. *Thorax*. 2001 Feb;56(2):133-7.
- Lopez-Jimenez F, Kuniyoshi FHS, Gami A, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. *Chest*. 2008 Mar;133(3):793-804.
- Imagawa S, Yamaguchi Y, Ogawa K, Obara N, Suzuki N, Yamamoto M, et al. Interleukin-6 and tumor necrosis factor- α in patients with obstructive sleep apnea-hypopnea syndrome. *Respiration*. 2004 Jan/Feb;71(1):24-9.
- World Health Organization (WHO). Information note on COVID-19 and NCDs [Internet]. Geneva: WHO; 2020; [access in 2020 Mar 23]. Available from: <https://www.who.int/internal-publications-detail/covid-19-and-ncds>
- Costa D, Barbalho MC, Miguel GPS, Forti EMP, Azevedo JLMC. The impact of obesity on pulmonary function in adult women. *Clinics*. 2008 Dec;63(6):719-24.
- Carrascal L, Nunez-Abades P, Ayala A, Cano M. Role of melatonin in the inflammatory process and its therapeutic potential. *Curr Pharm Des* [Internet]. 2018; 24(14):1563-88. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29701146>
- Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. *Clin Immunol* [Internet]. 2020 May; 214:108393. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1521661620301984>
- Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. *Cell Host Microbe* [Internet]. 2016 Feb; 19(2):181-93. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1931312816300063>
- McSharry D, Malhotra A. Potential influences of obstructive sleep apnea and obesity on COVID-19 severity. *J Clin Sleep Med* [Internet]. 2020 May; 16(9):1645. Available from: <http://jcs.m.aasm.org/doi/10.5664/jcs.m.8538>

17. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region — case series. *N Engl J Med* [Internet]. 2020 May; 382(21):2012-22. Available from: <http://www.nejm.org/doi/10.1056/NEJMoa2004500>
18. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. *JAMA* [Internet]. 2020 Apr; 323(16):1612-14. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2763485>
19. Nunes JOF, Apostolico JS, Andrade DAG, Ruiz FS, Fernandes ER, Andersen ML, et al. Sleep deprivation predisposes allergic mice to neutrophilic lung inflammation. *J Allergy Clin Immunol* [Internet]. 2018 Mar; 141(3):1018-1027.e4. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0091674917311053>
20. Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med* [Internet]. 2017 Mar; 13(03):479-504. Available from: <http://jcs.m.aasm.org/doi/10.5664/jcs.m.6506>
21. Salles C. Correspondence COVID-19: melatonin as a potential adjuvant treatment. *Life Sci* [Internet]. 2020 Jul; 253:117716. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0024320520304641>
22. Salles C, Barbosa H. COVID-19 and obstructive sleep apnea. *J Clin Sleep Med*. 2020 Sep;16(9):1647.
23. Tufik S, Gozal D, Ishikura IA, Pires GN, Andersen ML. Does obstructive sleep apnea lead to increased risk of COVID-19 infection and severity?. *J Clin Sleep Med*. 2020 Aug;16(8):1425-6.
24. Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. *Pharmacother J Hum Pharmacol Drug Ther* [Internet]. 2020 May; 40(5):416-37. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/phar.2398>
25. Grote L, McNicholas WT, Hedner J. Sleep apnoea management in Europe during the COVID-19 pandemic: data from the European Sleep Apnoea Database (ESADA). *Eur Respir J* [Internet]. 2020 Jun; 55(6):2001323. Available from: <http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01323-2020>